Simon Molgaard, PhD, is co-inventor of key Teitur patents. Author of key neuroscience publications over the last 10 years. Has led research, operations, financing and initiation of key collaborations for this project since 2015. Former visiting scientist at Mayo Clinic, US.
Anders, MSc in Molecular Medicine, has headed preclinical research for Teitur and is co-inventor of key Teitur patents. His research fields include molecular neuroscience, cell biochemistry, molecular imaging and structural-activity relationships of peptides.
Ed has over 20 years experience in drug discovery and development, spanning big Pharma, CRO, biotech and consultancy roles supporting the successful progression of a number of projects to the clinic. At Teitur he is leading the preclinical development of TT-P34 and the projects progression to the clinic.
Mathias Kaas Ollendorff, MD, has 10+ years experience in neuroscience with particular focus on behavioural phenotyping of sortilin receptor transgenic models. He has guided the testing of Teitur peptides in animal models of neurodegeneration and the assessment of pharmacokinetic properties.
With over 15 years of experience in the biotechnology and pharmaceutical industries, Andreas brings a deep expertise in clinical development and strategic study planning to Teitur. Throughout his career he has worked with leading companies such as Merz Pharmaceuticals, Boehringer Ingelheim, Corlieve Therapeutics, and UniQure, where he has played a key role in advancing multiple programs through the clinical development phase. His leadership is instrumental in driving the clinical development of TT-P34 as we continue our mission to develop innovative therapies for neurodegenerative diseases.
Maya leads ESG initiatives, GDPR compliance & human resources at Teitur Trophics. With a solid educational and practical background in administration, HR management and organizational development, Maya supports the focus on sustainability, GDPR compliance and evolvement and optimization of the Teitur operations.
Emil, PhD in Molecular Medicine, has a rich background in neuroscience (10 years), including extensive experience in cellular and molecular research within neurodegenerative diseases and in particular Parkinson’s Disease.
Anne Kathrine, PhD in Clinical Medicine, has an extensive background (10 years) in glucose and lipid dysregulation at molecular level in metabolic diseases. Her research spans multiple fields where her creative biotechnology engineer intersects with her extensive experience in bridging basic scientific and clinical research.
Sanne has nearly 20 years of experience in biochemistry and molecular biology techniques and has worked within multiple fields of research including neurodegenerative and metabolic diseases and psychriatric disorders.
Mia leads Project Management at Teitur Trophics supporting the alignment of the project teams and ensuring good communication between all internal and external parties. With a solid background in academic and biotech research managing preclinical in vivo studies, alongside management of project timelines for key deliverables Mia works to keep progression of our lead assets on track
Sunita has over 25 years of clinical research experience supporting early and late phase drug development in both biotech and big Pharma. Sunita has oversight of the clinical stage portfolio and managing the full-service outsourcing of clinical studies.
